741699-47-8

Basic information

• Product Name: 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanol
• Synonyms: 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanol;2-[4-(Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethan-1-ol;(4-(2-HYDROXYETHOXY)PHENYL)BORONIC ACID PINACOL ESTER
• CAS NO: 741699-47-8
• Molecular Formula: C₁₄H₂₁BO₄
• Molecular Weight: 264.13
• EINECS: -0
• Mol File: 741699-47-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 391.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.22±0.10(Predicted)
• CAS DataBase Reference: 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanol(741699-47-8)
• EPA Substance Registry System: 2-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanol(741699-47-8)

Safety Data

• Hazardous Substances Data: 741699-47-8(Hazardous Substances Data)

Usage

Class

Boronic acid ester

Common Uses

Reagent in organic synthesis
Particularly used in medicinal and pharmaceutical chemistry

Structure

Phenolic structure with an attached boronic acid group

Chemical Reactions

Participates in Suzuki-Miyaura coupling and other cross-coupling reactions
Important building block for the synthesis of various biologically active molecules

Characteristics

Mild reaction conditions
High efficiency in forming carbon-carbon bonds

Additional Applications

Stabilizer and cross-linking agent in polymer and material production

Upstream product

• 34743-88-9 2-(4-bromophenoxy)ethanol 
• 73183-34-3 bis(pinacol)diborane 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 269410-28-8 ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)acetate 

Downstream Products

• 741699-48-9 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl methanesulfonate 

Relevant articles and documents

NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula: wherein R1 to R6 and A are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides novel compounds having the general formula: wherein R1 to R11 are as described herein, compositions including the compounds and methods of using the compounds.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.